The last full weekend of each month, our editorial team compiles a list of our most popular rheumatology content from the past month for a month in review recap. The January 2023 rheumatology month in review highlights a recent study that observed an increased risk of hospitalization and death among patients with gout and COVID-19, the expansion of research evaluating adalimumab biosimilars, and trends in fibromyalgia. However, as one study reported, patients with rheumatoid arthritis (RA) switching to a biosimilar for a non-medical reason led to worse outcomes. Those switching to adalimumab biosimilars from the bio-originator were placed in the “switchers” category. Investigators enrolled patients with fibromyalgia at the Fibromyalgia and Chronic Pain Center, at California State University, Fullerton.

Source: New York Times January 30, 2023 03:13 UTC